Drug intelligence / Profile preview

IMOSkin

Development stage: Preclinical
Lead developer: WEIR Science
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

IMOSkin is a topical botanical and fermentation-derived complex under development by WEIR Science. It is designed to support cellular skin health by regulating apoptosis and cell-renewal pathways. The product is intended for topical application to maintain and improve skin health through the modulation of cellular turnover and programmed cell death mechanisms. As of 2024, IMOSkin is in the preclinical development stage, with further advancement and potential clinical entry planned for 2025. The specific molecular targets and the exact composition of the botanical complex have not been publicly disclosed.

Brand names: IMOSkin
Other names: IMOSkin

Beyond the preview

Go deeper on IMOSkin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMOSkin.

Explore the full profile